Skip to main content

Healthcare, Life Sciences and Pharmaceuticals · Published Aug 2026

Veterinary Care Market

The veterinary care market is projected to expand from USD 9,721.38 million in 2025 to USD 19,666.41 million by 2035, reflecting a compound annual growth rate (CAGR) of 7.3%. Growth is driven by rising pet ownership, increased focus on preventive care, and advancements in veterinary diagnostics and telehealth technologies. The market is segmented by treatment type into No medicalization, Basic Medicalization, and Under Long Term Veterinary Care, and by animal type including Dogs, Cats, Cattle, Horses, Pigs, and Poultry.

North America leads the market, supported by robust regulatory frameworks and high pet humanization trends.

Report scope & segmentation

Veterinary Care Market by Treatment Type (No medicalization, Basic Medicalization, and Under Long Term Veterinary Care), Animal Type (Dogs, Cats, Cattle, Horses, Pigs, and Poultry), And by Region (North America, Europe, Asia Pacific, South America, Middle East, and Africa), Global Trends and Forecast From 2026 To 2035

Market size

Growth trajectory through 2035

$9.72 Bn Base 2025
↑ 7.30% CAGR 2025–2035
$19.66 Bn Forecast 2035

Veterinary Care Market · Market size 2025–2035

Base year 2025 · Forecast 2035 · USD Billion

Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.

What this shows

The Veterinary Care Market is projected to reach $19.66 Bn by 2035, up from $9.72 Bn in 2025 — a 7.30% CAGR equating to roughly 2.0× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.

What's new in this edition

Here's what changed

This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.

Recent developments tracked

  1. Development 01 Telehealth integration
    • Platforms such as Airvet and Vetster expanded veterinary telehealth services, enabling remote consultations and diagnostics.
  2. Development 02 Diagnostic advancements
    • Companies like IDEXX and Zoetis launched new veterinary diagnostic kits, improving early disease detection in companion and livestock animals.
  3. Development 03 Regulatory updates
    • New animal welfare regulations in North America and Europe are driving demand for compliant veterinary services and products.

Emerging opportunities added

  • Telehealth expansion Digital platforms for remote consultations and diagnostics are expected to grow, addressing access gaps in rural and underserved regions.
  • Diagnostic innovation Advances in veterinary diagnostic kits enable early disease detection, reducing economic losses in livestock and companion animals.
  • Regional growth in Asia-Pacific Urban pet ownership and government veterinary infrastructure programs are accelerating market expansion.

Executive snapshot

The four things that matter

A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.

Market size · 2025–2035

$19.66 Bn

forecast for 2035

2025 base
$9.72 Bn
CAGR
7.30%
Expansion
2.0×

Market shape

North America

leading region

Leading region
North America
Top-5 concentration
Low to medium · ~42%

Forces at play

Rising pet ownership

▲ top tailwind

▼ headwind
Regulatory hurdles
Named players
15 profiled
Growth peak
2027–2031

Latest development

Latest tracked

Telehealth integration: Platforms such as Airvet and Vetster expanded veterinary telehealth services, enabling remote consultations and diagnostics

+2 more tracked in this edition

Report scope

What this report answers

The specific decisions and questions covered in the 138-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.

  • How big is the Veterinary Care Market today ($9.72 Bn base), and how fast will it grow at 7.3% CAGR through 2035?
  • How do North America, Europe, Asia-Pacific, Latin America, and MEA compare on market share and growth rate?
  • Where do Zoetis Inc, Boehringer Ingelheim Animal Health, Merck Animal Health and 12 other named players sit in market share, tier, and product breadth?
  • What are the top growth drivers (led by Rising pet ownership) and top restraints (led by Regulatory hurdles), with quantified CAGR impact?
  • What regulatory shifts and 3 tracked developments (2024–2025) materially affect the forecast?
  • Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?

Market dynamics

Why the number moves this way

The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.

Growth drivers

Pulling the market up

  • Rising pet ownership Approximately 67% of U.S. households own a pet, driving demand for veterinary services and preventive care.
  • Preventive care adoption Shift from reactive to proactive veterinary care, including wellness exams and early disease detection.
  • Technological advancements Growth in veterinary telehealth, diagnostic kits, and artificial insemination technologies enhancing service accessibility and efficiency.
  • Regulatory support Strengthened animal welfare regulations and standards improving service quality and trust in veterinary practices.

Restraints

Holding it back

  • Regulatory hurdles Approval timelines for veterinary pharmaceuticals and devices may extend by 6-12 months post-2025.
  • Supply chain constraints Component shortages for veterinary instruments and diagnostics persisted through H1 2025.
  • High operational costs Veterinary clinics face rising costs of specialized equipment and skilled labor, impacting affordability.

Impact analysis

Quantified drivers & restraints

Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.

Driver% Impact on CAGRGeographic RelevanceImpact Timeline
Rising pet ownership +3.3% Global 2025–2035
Preventive care adoption +2.0% Global 2025–2035
Technological advancements +1.6% Global 2025–2035
Regulatory support +1.1% Global 2025–2035

Restraints impact analysis

Restraint% Impact on CAGRGeographic RelevanceImpact Timeline
Regulatory hurdles −1.3% Global 2025–2029
Supply chain constraints −0.9% Global 2025–2029
High operational costs −0.7% Global 2025–2029

The veterinary care market is segmented by treatment type into No medicalization, Basic Medicalization, and Under Long Term Veterinary Care. By animal type, the market includes Dogs, Cats, Cattle, Horses, Pigs, and Poultry. Companion animals (dogs and cats) dominate the market, while livestock segments reflect regional agricultural priorities.

Geography

Regional market share

Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.

Regional share · 2025

SHARE OF $9.72 BN BASE MARKET

Bars sized to relative regional share. Leader region highlighted in gold.

What this shows

North America leads regional demand at ~42.8% in 2025. Driven by manufacturing scale and end-market density.

Competitive landscape

Who's competing, and how

The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.

The veterinary care market is consolidated among global pharmaceutical and animal health firms, including Pfizer, Johnson & Johnson, Merck, Novartis, Roche, AbbVie, Eli Lilly, AstraZeneca, GSK, and GlaxoSmithKline. Key players focus on product innovation, strategic partnerships, and regional expansion to strengthen market presence.

Concentration snapshot

Top 5 players control ~35–50% of the market

Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.

Top 5 players Rest of market
~43%
~58%

Competitive tiers

Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.

Tier 1 · Leaders

3companies

Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.

Tier 2 · Challengers

5companies

Regional strongholds, focused portfolio, actively expanding via M&A or capacity.

Tier 3 · Emerging

7companies

Niche or early-stage, differentiated technology or early-mover positioning.

Named players covered

Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.

  • Zoetis Inc

    Leading player · Full profile in the report

    Rank 01
    Share est. ~16%
    Revenue $■■■M
    HQ ■■■
  • Boehringer Ingelheim Animal Health

    Profiled · Full detail in the report

    Rank 02
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Merck Animal Health

    Profiled · Full detail in the report

    Rank 03
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Elanco Animal Health

    Profiled · Full detail in the report

    Rank 04
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Ceva Sante Animale

    Profiled · Full detail in the report

    Rank 05
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Virbac SA

    Profiled · Full detail in the report

    Rank 06
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • Vetoquinol SA

    Profiled · Full detail in the report

    Rank 07
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■
  • IDEXX Laboratories

    Profiled · Full detail in the report

    Rank 08
    Share ■■.■%
    Revenue $■■■M
    HQ ■■■

+ 7 more player profiles in the full report.

Unlock the full competitive landscape

Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.

Download sample

Regulatory landscape

Policy and standards affecting the forecast

Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.

  1. United States

    FDA · IRA drug pricing · CMS

    FDA CDER/CBER approves new drugs and biologics; typical NDA review 10 months (standard), 6 months (priority). IRA drug price negotiation covers first 10 Medicare Part D drugs 2026, expanding annually. CMS coverage decisions gate market access. State-level PBM reform + 340B changes reshape distribution.

  2. European Union

    EMA · HTA Reg · GDPR-health

    EMA centralised procedure mandatory for biotech, oncology, HIV, orphan drugs — 210-day evaluation timeline. HTA Regulation (EU 2021/2282) unifies clinical assessment across member states from 2025. Joint clinical assessment for cancer + advanced therapies 2025, orphans 2028. GDPR + national health data laws govern secondary use of clinical data.

  3. China / APAC

    NMPA · VBP · NRDL

    NMPA reform since 2015 reduced approval times from 5+ years to ~14 months; ICH-aligned data acceptance. Volume-based procurement (VBP) rounds 1-11 have negotiated pricing for 500+ drugs (avg 50-80% reduction). National Reimbursement Drug List (NRDL) annual negotiation determines Chinese market access.

  4. Global standards

    ICH · WHO · Pharmacopoeia

    ICH (International Council for Harmonisation) guidelines adopted by FDA, EMA, PMDA, NMPA, Health Canada, and Swissmedic. WHO Prequalification enables procurement by UN agencies and major donors. USP, EP, JP pharmacopoeia standards govern drug quality worldwide. GxP quality standards (GCP, GMP, GLP, GVP) universal.

Purchase options

License this report

All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.

Individual

Single user

$3,499

  • 1 named user, non-transferable
  • Full PDF + Excel data pack
  • 1 hour analyst clarification call
Buy Now Request sample
Enterprise

Corporate

$5,499

  • Unlimited users org-wide
  • Full PDF + Excel data pack
  • 4 hours analyst time
  • Presentation-ready deck
Buy Now Request sample

Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.

How buying works

  1. 01 Select a license — your enquiry reaches the desk lead within one business day.
  2. 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
  3. 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.

Payment methods accepted

  • PayPalGlobal
  • RazorpayCards · UPI · Netbanking
  • Visa · Mastercard · AmexVia gateway
  • Wire transferUSD · EUR · INR · GBP
  • Corporate PONet-30 on approval

Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.

Methodology

How we built this estimate

Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.

  1. Primary research

    Interviews · surveys

    Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.

  2. Secondary research

    Filings · associations · databases

    Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.

  3. Data triangulation

    Three independent paths

    Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.

  4. Analyst review

    Senior sign-off

    Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.

Frequently asked questions

Common questions about this report

  • ● What is the worth of the global veterinary care market?
    The Veterinary care market size has crossed USD 5.9 billion in 2020 and will observe a CAGR of more than 7.3% up to 2027 driven by the rising technological advancements in care processes.
  • ● What is the size of the North America veterinary care industry?
    North America held more than 38% of the veterinary care market revenue share in 2020 and will witness expansion with the surging demand for veterinary care in countries, including U.S. and Canada.
  • ● What are the upcoming trends of the veterinary care market, globally?
    The upcoming trends in the veterinary care market are expansion in the technological advancements in veterinary care will drive industry revenue in the next few years
  • ● What is the CAGR of theveterinary care market?
    The global veterinary care market registered a CAGR of 7.3% from 2022 to 2029. The application segment was the highest revenue contributor to the market, with 5.9 billion in 2020, and is estimated to reach 11.2 million by 2029, with a CAGR of 8%.
  • ● Which are the top companies to hold the market share in theveterinary care market?
    Key players profiled in the report include Zoetis (US), Merck (US), Boehringer Ingelheim (Germany), Elanco (US), Ceva (France), Phibro Animal Health Corporation (US), Virbac SA (France), IDEXX Laboratories, Inc., Neogen Corporation (US), Heska Corporation (US) and others.
  • ● What is the leading application of the veterinary care market?
    The Basic medicalization market segment type dominated the market.
  • ● Which is the largest regional market for veterinary care market?
    North America is the largest regional market for veterinary care.